NCT05378464 2026-04-01
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
Clinical Trials
12 trialsNCT06435351 2026-04-01
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT04943848 2026-03-17
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Recruiting
NCT06011772 2026-03-11
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
NCT04015700 2026-02-09
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT04948619 2026-01-22
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT05264974 2026-01-21
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
Phase 1 Recruiting
NCT01720836 2025-10-21
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
University of Pittsburgh
Phase 1/2 Recruiting
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT04523688 2025-07-22
Combi G-Vax
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT00505063 2025-06-15
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed